Healthcare
Live Price
Offline$4.26
+0.00% today
1Y Change
-16.47%
Window
Jun 30, 2025 → Jun 24, 2026
Coverage: 253 bars · Jun 30, 2025 → Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
JD Health International Inc. (JDHIY) is a Healthcare stock with a market cap of $126.79B and listed on OTC. The stock last traded around $4.26 and down 16.5% across the available one-year price window (Jun 30, 2025 → Jun 24, 2026). Baseline metrics include revenue growth of +22.8%, EPS growth of +27.3%, a dividend yield of 0.0%. What stands out right now is revenue +22.8%, EPS +27.3%, free cash flow -100.0% with operating margin 5.3% and ROIC 5.6%. Valuation is more restrained than many high-expectation growth names at P/E 23.8 and price/sales 1.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines JDHIY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
JDHIY is 35.15 pts behind over the shared 1Y window.
JDHIY had 43.95 pts deeper max drawdown than SPY.
JDHIY beat SPY in 1 of 2 calendar years shown and trailed in 1.
JDHIY
-16.47%
Normalized return
SPY
+18.68%
S&P 500
Excess Return
-35.15 pts
Relative to SPY
JDHIY Max Drawdown
-53.08%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for JDHIY and SPY.
| Year | JDHIY | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | -53.08% | +6.71% | -59.79 pts | SPY |
| 2025 | +78.04% | +11.19% | +66.85 pts | JDHIY |
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$30.7B
-34.4% YoY
FY Net Income
-$1.1B
-382.4% YoY
Free Cash Flow
$2.9B
-19.8% YoY
Revenue Growth
+22.8%
EPS Growth
+27.3%
Gross Margin
24.8%
Net Margin
7.3%
Income statement
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 71.4B | 58.2B | 53.5B | 46.7B | 30.7B |
| Gross Profit | 17.7B | 13.3B | 11.9B | 9.9B | 7.2B |
| Operating Income | 3.7B | 1.5B | 631M | 803M | -857M |
| EBITDA | 4.0B | 5.0B | 858M | 944M | -832M |
| Net Income | 5.2B | 4.2B | 2.1B | 380M | -1.1B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 31.8B | 22.6B | 15.0B | 18.7B | 17.3B |
| Total Assets | 81.6B | 71.3B | 64.3B | 61.3B | 48.0B |
| Total Liabilities | 21.5B | 16.0B | 14.9B | 16.5B | 8.1B |
| Shareholder Equity | 60.1B | 55.2B | 49.4B | 44.8B | 39.9B |
| Total Debt | 636M | 258M | 215M | 199M | 201M |
| Net Debt | -31.2B | -22.4B | -14.8B | -18.5B | -17.1B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
3.4B
-41.9% YoY
Capital Expenditures
518M
+77.2% YoY
Free Cash Flow
2.9B
-19.8% YoY
Key ratios
Gross Margin
24.8%
Operating Margin
5.3%
Net Margin
7.3%
ROE
9.0%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.